Treatment Options for Brain Cancer

Learn about the latest treatments for advanced brain cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.

What I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her.

Marilou
Cervical cancer survivor

New Brain Cancer Molecular Testing Options

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, key tumor mutations, methylation patterns, other biomarkers, and precision medicine.

Latest Clinical Trial Results in Brain Cancer

Some of the most promising new treatments for advanced brain cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • Bevacizumab and Temozolomide in First Recurrence of Glioma Without 1p/19q Codeletion

    Emma Shtivelman, PhD

    Excerpt from The ASCO Post:

    “In a phase II trial funded by the European Organisation for Research and Treatment of Cancer and reported in The Lancet Oncology, van den Bent et al found no evidence of a survival benefit with the addition of bevacizumab (Avastin) to temozolomide in patients with a first recurrence of World Health Organization grade II or III glioma without the 1p/19q codeletion.

    “In the open-label trial, conducted at 32 European centers, 155 patients were randomized between February 2011 and July 2015 to receive either temozolomide at 150 to 200 mg/m² on days 1 to 5 every 4 weeks for a maximum of 12 cycles (n = 77) or the same temozolomide regimen plus bevacizumab at 10 mg/kg every 2 weeks until disease progression (n = 78). Previous chemotherapy must have been stopped at least 6 months before enrollment, and radiotherapy, at least 3 months before enrollment. Overall, 44% of patients in the combination group and 47% in the temozolomide group had grade III disease.”

    Go to full article published by The ASCO Post on Aug 20, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • First Patient Dosed in Phase I/II Trial of Novel Immunotherapy Combination in Newly Diagnosed Glioblastoma

    Emma Shtivelman, PhD

    Excerpt from Targeted Oncology:

    “The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma (GBM). Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.

    “This study aims to investigate the efficacy of INO-5401, a T-cell activating immunotherapy agent encoding multiple antigens in GBM, and INO-9012, an immune activator encoding IL-12, in combination with the PD-1 inhibitor cemiplimab (REGN2810).”

    Go to full article published by Targeted Oncology on July 9, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • Show More
Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

E. David Crawford, MD
Cancer Commons Advisor

Living With Cancer

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

Patient Stories

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

The Big Picture

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

Cancer and Covid-19

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.